Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCOZJY)

Drug Name
Tenapanor Drug Info
Synonyms
1234423-95-0; UNII-WYD79216A6; AZD 1722; WYD79216A6; AZD-1722; 3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide; Tenapanor [USAN:INN]; Tenapanor(free base); GTPL8449; CHEMBL3304485; SCHEMBL15267600; DTXSID40154016; BCP24892; BCP28554; EX-A2506
Indication
Disease Entry ICD 11 Status REF
Irritable bowel syndrome DD91.0 Approved [1]
Constipation DD91.1 Phase 2 [2]
Kidney disease GC2Z Phase 2 [3]
Cross-matching ID
PubChem CID
71587953
CAS Number
CAS 1234423-95-0
TTD Drug ID
DMCOZJY
INTEDE Drug ID
DR1549
ACDINA Drug ID
D01472

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium/hydrogen exchanger 3 (SLC9A3) TTFZVPO SL9A3_HUMAN Modulator [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Approved [4]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Approved [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Sodium/hydrogen exchanger 3 (SLC9A3) DTT SLC9A3 2.202 2.678 4.154 2.406
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 10.08 7.207 5.403 9.211
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 13 Disease of the digestive system
Disease Class ICD-11: DD91 Irritable bowel syndrome
The Studied Tissue Rectal colon tissue
The Studied Disease Irritable bowel syndrome [ICD-11:DD91.0]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Sodium/hydrogen exchanger 3 (SLC9A3) DTT SLC9A3 6.83E-01 -0.03 -0.13
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 8.83E-03 1.59E-01 4.32E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.40E-01 -2.17E-02 -4.03E-02
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 ClinicalTrials.gov (NCT01340053) A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT01764854) Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis. U.S. National Institutes of Health.
4 FDA label of Tenapanor. The 2020 official website of the U.S. Food and Drug Administration.